Serious adverse event at 24±6 months · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in claudication distance from baseline (m) · intermittent claudication
1 finding from 1 review
Quality of life (change in points, SF‐36, WIQ) · intermittent claudication
1 finding from 1 review
Absolute claudication distance (change in metres) · intermittent claudication
1 finding from 1 review
Arterial revascularisation · intermittent claudication
It is very uncertain whether cilostazol changes arterial revascularisation (number of cases) compared with placebo (very low certainty).
1 finding from 1 review
Amputation · intermittent claudication
It is very uncertain whether cilostazol changes amputation (number of cases) compared with placebo (very low certainty).
1 finding from 1 review
Adverse event related to study medication ‐ headache (number of cases) · intermittent claudication
Cilostazol probably leads to higher adverse event related to study medication ‐ headache (number of cases) compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular events · intermittent claudication
Cilostazol showed no clear difference in cardiovascular event (number of cases) compared with placebo (low certainty).
1 finding from 1 review
Number of cases of dementia Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
It is very uncertain whether antihypertensive therapy changes number of cases of dementia Range of compared with placebo (very low certainty).
1 finding from 1 review
Change in MMSE · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review
Systolic blood pressure (mmHg), change from baseline · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review
Diastolic blood pressure (mmHg), change from baseline · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review
Adverse effects Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review
Quality of life measured via Sickness Impact Profile, PGWB Positive well‐being, and EuroQoL Current Health Range of · participants without prior cerebrovascular disease for prevention of cognitive impairment and dementia
1 finding from 1 review
Clinical response of depression · adults with psychotic depression
It is very uncertain whether antidepressant changes clinical response of depression compared with placebo (very low certainty).
1 finding from 1 review
Change in depression severity from baseline · adults with psychotic depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with psychotic depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ dropouts due to adverse effects · adults with psychotic depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · adults with psychotic depression
It is very uncertain whether antidepressant changes overall dropouts compared with placebo (very low certainty).
1 finding from 1 review
Clinical response of depression · adults with psychotic depression
It is very uncertain whether antidepressant plus antipsychotic changes clinical response of depression compared with placebo (very low certainty).
1 finding from 1 review